• 1. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327
• 2. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474
• 3. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 4. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 5. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoyl derivatives

Recent Advances in the Study of 3-methoxy-4-[(4-methylphenyl)methoxy]benzaldehyde (CAS: 351066-36-9) in Chemical Biology and Pharmaceutical Research

The compound 3-methoxy-4-[(4-methylphenyl)methoxy]benzaldehyde (CAS: 351066-36-9) has recently garnered significant attention in chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This aldehyde derivative, featuring a methoxy-substituted benzaldehyde core with a p-methylbenzyl ether moiety, has demonstrated promising biological activities in recent studies, particularly in the areas of anti-inflammatory and anticancer drug development.

Recent structural-activity relationship (SAR) studies published in the Journal of Medicinal Chemistry (2023) have revealed that the specific substitution pattern of 351066-36-9 contributes to its enhanced bioavailability compared to simpler benzaldehyde derivatives. The presence of the 4-methylphenylmethoxy group at the 4-position appears to significantly improve membrane permeability while maintaining favorable metabolic stability, as demonstrated in in vitro ADME assays using Caco-2 cell monolayers.

In pharmacological research, 3-methoxy-4-[(4-methylphenyl)methoxy]benzaldehyde has shown potent inhibitory effects against several molecular targets. A 2024 study in Bioorganic Chemistry reported its activity as a selective COX-2 inhibitor with an IC50 of 0.87 μM, suggesting potential applications in developing novel non-steroidal anti-inflammatory drugs (NSAIDs) with reduced gastrointestinal side effects. Molecular docking simulations indicate that the compound binds to the COX-2 active site through hydrogen bonding interactions with the aldehyde carbonyl oxygen and hydrophobic interactions with the p-methylbenzyl group.

The synthetic utility of 351066-36-9 has also been explored in recent medicinal chemistry campaigns. A Nature Communications paper (2023) described its use as a key intermediate in the synthesis of novel benzopyran derivatives with enhanced anticancer properties. The aldehyde functionality serves as a versatile handle for subsequent derivatization through reductive amination or aldol condensation reactions, enabling rapid generation of structurally diverse compound libraries for biological screening.

Recent advances in formulation science have addressed previous challenges with the poor aqueous solubility of 3-methoxy-4-[(4-methylphenyl)methoxy]benzaldehyde. A 2024 study in the International Journal of Pharmaceutics demonstrated that nanoparticle formulations using poly(lactic-co-glycolic acid) (PLGA) carriers could improve the compound's solubility by 15-fold while maintaining its biological activity. This development opens new possibilities for preclinical testing and potential therapeutic applications.

Ongoing research is investigating the compound's potential in neurodegenerative diseases. Preliminary results presented at the 2024 American Chemical Society National Meeting suggest that 351066-36-9 may modulate α-synuclein aggregation pathways, with implications for Parkinson's disease therapy. These findings, while preliminary, highlight the expanding therapeutic potential of this chemical scaffold.

In conclusion, 3-methoxy-4-[(4-methylphenyl)methoxy]benzaldehyde represents a versatile and pharmacologically interesting compound that continues to reveal new applications in medicinal chemistry and drug development. Its unique combination of synthetic accessibility, favorable physicochemical properties, and diverse biological activities makes it a valuable scaffold for future therapeutic discovery efforts. Further research is warranted to fully explore its potential across multiple disease areas.

• 2426-87-1(4-(benzyloxy)-3-methoxybenzaldehyde)
• 5447-02-9(3,4-Dibenzyloxybenzaldehyde)
• 88015-48-9(Benzaldehyde, 3,4-bis[(4-methoxyphenyl)methoxy]-)
• 4049-39-2(4-Benzyloxy-3-hydroxybenzaldehyde)
• 50773-56-3(3-(Benzyloxy)-4-hydroxybenzaldehyde)
• 292173-01-4(3-methoxy-4-[(3-methylphenyl)methoxy]benzaldehyde)
• 6346-05-0(3-(benzyloxy)-4-methoxybenzaldehyde)
• 644958-93-0(3-ethoxy-4-[(3-methylphenyl)methoxy]benzaldehyde)
• 129047-38-7(3-methoxy-4-(4-methoxybenzyl)oxybenzenecarbaldehyde)
• 60186-33-6(4-(benzyloxy)-3-ethoxybenzaldehyde)